FindTrial
Sign In

Glumetinib

DRUG4 trials

Sponsors

Haihe Biopharma Co., Ltd., Shanghai JMT-Bio Inc.

Conditions

C-Met Exon 14 MutationHealthy VolunteersNegative T790M Mutation and Met AmplificationNon-Small Cell Lung Cancer

Phase 1

Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer
RecruitingNCT04270591
Haihe Biopharma Co., Ltd.C-Met Exon 14 Mutation
Start: 2019-07-15End: 2023-12-30Target: 183Updated: 2022-08-01
Glumetinib Combined With Osimertinib in the Treatment of Relapsed and Metastatic Non-small Cell Lung Cancer Patients Who Failed to Receive EGFR Inhibitors
NCT04338243
Haihe Biopharma Co., Ltd.Negative T790M Mutation and Met Amplification
Start: 2019-11-18End: 2020-12-31Target: 70Updated: 2020-04-08
Single Dose Glumetinib in Healthy Chinese Male Subjects
CompletedNCT05507294
Haihe Biopharma Co., Ltd.Healthy Volunteers
Start: 2021-03-02End: 2021-09-30Updated: 2022-08-19

Phase 3

A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in Non-Small Cell Lung Cancer Patients After Resistance to EGFR-TKIs
RecruitingNCT06829459
Shanghai JMT-Bio Inc.Non-Small Cell Lung Cancer
Start: 2025-04-03End: 2029-02-15Target: 350Updated: 2025-04-08

Related Papers

Long-term follow-up results from the GLORY study: phase II study of gumarontinib in East Asian patients with <i>MET</i> exon 14 skipping mutated non-small cell lung cancer.
2025-09-28
Cost-effectiveness analysis of gumarontinib versus savolitinib for the treatment of advanced or metastatic NSCLC with MET exon 14 skipping mutations in China using partitioned survival model
Frontiers in Pharmacology2025-01-241 citations
A pooled analysis of clinical outcome in driver-gene negative non-small cell lung cancer patients with MET overexpression treated with gumarontinib.
2024-07-311 citations
Gumarontinib in patients with non-small-cell lung cancer harbouring <i>MET</i> exon 14 skipping mutations: a multicentre, single-arm, open-label, phase 1b/2 trial.
2023-04-0649 citations